The risk of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) among cancer patients.
Bipartisan House group calls on FDA to ensure OTC and prescription versions of a drug cannot be marketed simultaneously
Reps. Debbie Dingell (D-MI), Robert Latta (R-OH) and Dan Crenshaw (R-TX) sent a letter yesterday to Patrizia Cavazzoni, the head of FDA’s Center for Drug